Dutton Associates recently rated Pressure BioSciences, Inc. (NASDAQ: PBIO) as a “Speculative Strong Buy,” pricing the 12-month target at $10 per share. The research report commends the company on its “unique and superior technology” applicable to a variety of areas in the life-sciences field.
As Pressure BioSciences utilizes its expanded sales force, Dutton said it expects sales to increase in the upcoming quarters of 2008. The company’s Commercialization Plan called for the addition of seven full-time sales directors to help the company spread its regional coverage.
The sales force is responsible for the marketing of the Barocylcer NEP3229, the Barocycler NEP2320, PULSE Tubes (used in conjunction with the Barocyclers), and the company’s most recent product, ProteoSolve.
The company’s base technology is Pressure Cycling Technology (PCT), a sample preparation system that uses rapid, repeated, alternating cycles of hydrostatic pressure for cell component extraction. The company’s technology and instruments are used to further studies against obesity and related diseases through the research and development of sample preparation for genomic, proteomic and small molecule studies.
In November 2007, Pressure BioSciences announced an increase in its sales of the Barocycler NEP 3229 and an order from its manufacturer for 20 additional units. It also announced the installation of four Barocycler NEP2320 instruments, and an order for 40 more units from the company’s manufacturer.
Let us hear your thoughts: Pressure BioSciences, Inc. Message Board
